Research Article | | Peer-Reviewed

Progressive Urological Complications of Advanced Gynecological Cancers in Guinea: Epidemiological, Clinical and Therapeutic Aspects

Received: 1 February 2026     Accepted: 12 February 2026     Published: 14 April 2026
Views:       Downloads:
Abstract

Introduction: Progressive urological complications represent a urological emergency and an unfavorable prognostic factor in advanced gynecological cancers. This study aimed to describe the epidemiological, clinical, therapeutic, and evolutionary aspects of these complications at the Ignace Deen University Hospital in Conakry. Methodology: Prospective cross-sectional descriptive study conducted in the urology department of Ignace Deen University Hospital over 2 years (January 2024-December 2025). This study included patients with gynecological cancer presenting progressive urological complications. Variables studied were demographic (age, parity), clinical (histological type, FIGO stage, ECOG performance status), paraclinical (serum creatinine, hemoglobin, ultrasound), therapeutic (urinary drainage, oncological treatments), and evolutionary. Upper urinary tract drainage was performed by percutaneous nephrostomy or JJ stent placement. Results: We recorded 88 patients who presented with gynecological cancer with progressive urological complications. The mean age of patients was 54.3±11.5 years. Cervical cancer represented 96.6% (squamous cell carcinomas), predominantly at stage IIIB (61.2%). The general condition of patients was severely deteriorated: 59.1% ECOG III and 40.9% ECOG IV. Isolated bilateral ureterohydronephrosis constituted the main complication (47.7%). JJ stent drainage was successful in 55.7% of patients, percutaneous nephrostomy in 22.7%, with a failure rate of 21.6%. Mean serum creatinine decreased from 10.1 to 6.5 mg/dl (36% reduction), hemoglobin increased from 6.9 to 10.0 g/dl. Exclusive palliative care was provided to 73.9% of patients, 21.6% received chemotherapy. Mean hospital stay was 6.2 days with in-hospital mortality of 11.4%. Conclusion: This study reveals that urological complications of gynecological cancers in Guinea are characterized by late diagnosis and limited therapeutic options. Despite the feasibility of urinary drainage, the massive recourse to palliative care underscores the poor prognosis. Priorities include HPV vaccination, early screening, strengthening of technical facilities, and development of appropriate palliative care structures.

Published in International Journal of Clinical Urology (Volume 10, Issue 1)
DOI 10.11648/j.ijcu.20261001.24
Page(s) 77-84
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2026. Published by Science Publishing Group

Keywords

Gynecological Cancers, Guinea, Nephrostomy, JJ Stent, Ureterohydronephrosis

References
[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394-424.
[2] Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Global Health. 2020; 8(2): e191-e203.
[3] Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, et al. Cervical cancer: A global health crisis. Cancer. 2017; 123(13): 2404-2412.
[4] Gebreselassie KH, Adamu TA, Beyene AD. Ureteral stenting in patients with locally advanced cervical cancer: Predictors of low success rate. Gynecol Oncol Rep. 2024 Aug 28; 55: 101491.
[5] Steevy Ndang Ngou Milama, Adrien Mougougou, Euloge Ibinga, Dimitri Mbethe, Audrey Bikene Bi Ntoutoume, et al. Prognosis of Hydronephrosis in Cervical Cancer at the Libreville Cancer Institute. Int J Clin Urol. 2022; 6(1): 45-50.
[6] Denny L, Quinn M, Sankaranarayanan R. Screening for cervical cancer in developing countries. Vaccinated. 2006; 24 Suppl 3: S3/71-77.
[7] Ahmed M, Lawal AT, Bello A, Sudi A, Awaisu M, Mahomet S, Oyelowo N, Tolani M, Hamza BK, Maitama HY. Ultrasound-guided percutaneous nephrostomy: Experience at Ahmadu Bello Teaching Hospital in Zaria. Nigerian Journal of Clinical Practice. 2017; 20(12): 1622-1625.
[8] Chung SY, Stein RJ, Landsittel D, Davies BJ, Cuellar DC, Hrebinko RL, et al. 15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. J Urol. 2004; 172(2): 592-595.
[9] Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev. 2017; 26(4): 444-457.
[10] Parkin DM, Bray F, Ferlay J, Jemal A. Cancer in Africa 2012. Cancer Epidemiol Biomarkers Prev. 2014; 23(6): 953-966.
[11] Sankaranarayanan R, Ferlay J. Worldwide burden of gynecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006; 20(2): 207-225.
[12] World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization; 2021.
[13] Ola IO, Okunowo AA, Habeebu MY. Mortality risk stratification based on comorbidity status among cervical cancer patients in Lagos, Nigeria. IntHealth. 2025 Sep 3; 17(5): 669-677.
[14] Nthambi L, Temmerman M, Macharia WM, Nyagol J, Mogere S, Neary J, Nyabs E, Itindi J, Langat A, Wangari E, Chung MH, Mwenda V, John-Stewart G, Singa B, McGrath CJ. Factors associated with cervical cancer screening among women attending maternal child health clinics in Kenya. BMC Womens Health. 2025 Nov 10; 25(1): 549.
[15] Denny L. Cervical cancer: prevention and treatment. Discov Med. 2012; 14(75): 125-131.
[16] Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012; 62(3): 147-172.
[17] World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2020.
[18] Dim CC, Ekwe E, Madubuko T, Dim NR, Ezegwui HU. Improved awareness of pap smear may not affect its use in Nigeria: a case study of female medical practitioners in Enugu, southeastern Nigeria. Trans R Soc Trop Med Hyg. 2009; 103(8): 852-854.
[19] Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009; 105(2): 107-108.
[20] Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019; 393(10167): 169-182.
[21] Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012; 460(3): 237-249.
[22] Ku JH, Lee SW, Jeon HG, Kim HH, Oh SJ. Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences? Urology. 2004; 64(5): 895-899.
[23] Lapitan MC, Buckley BS. Impact of palliative urinary diversion by percutaneous nephrostomy drainage and ureteral stenting among patients with advanced cervical cancer and obstructive uropathy: a prospective cohort. J Obstet Gynaecol Res. 2011 Aug; 37(8): 1061-70.
[24] Pavlovic K, Lange D, Chew BH. Stents for malignant ureteral obstruction. Asian J Urol. 2016 Jul; 3(3): 142-149.
[25] Ünal E, Çiftçi TT, Akhan O, Akinci D. Imaging-Guided De Novo Retrograde Ureteral Access and Stent Placement without Cystoscopy in Women. J Vasc Interv Radiol. 2023 May; 34(5): 902-909.
Cite This Article
  • APA Style

    Bah, M. D., Gamamou, A. V., Kanté, D., Sina, M. A., Cherif, A., et al. (2026). Progressive Urological Complications of Advanced Gynecological Cancers in Guinea: Epidemiological, Clinical and Therapeutic Aspects. International Journal of Clinical Urology, 10(1), 77-84. https://doi.org/10.11648/j.ijcu.20261001.24

    Copy | Download

    ACS Style

    Bah, M. D.; Gamamou, A. V.; Kanté, D.; Sina, M. A.; Cherif, A., et al. Progressive Urological Complications of Advanced Gynecological Cancers in Guinea: Epidemiological, Clinical and Therapeutic Aspects. Int. J. Clin. Urol. 2026, 10(1), 77-84. doi: 10.11648/j.ijcu.20261001.24

    Copy | Download

    AMA Style

    Bah MD, Gamamou AV, Kanté D, Sina MA, Cherif A, et al. Progressive Urological Complications of Advanced Gynecological Cancers in Guinea: Epidemiological, Clinical and Therapeutic Aspects. Int J Clin Urol. 2026;10(1):77-84. doi: 10.11648/j.ijcu.20261001.24

    Copy | Download

  • @article{10.11648/j.ijcu.20261001.24,
      author = {Mamadou Diawo Bah and Alexandre Vahina Gamamou and Daouda Kanté and Mamadou Abdoulahayo Sina and Aboubacar Cherif and Lahoumbo Ricardo Gnammi and Rémy François Akoï Guilavogui and Maïmouna Baldé and Thierno Mamadou Oury Diallo and Abdoulaye Bobo Diallo and Oumar Raphiou Bah and Telly Sy},
      title = {Progressive Urological Complications of Advanced Gynecological Cancers in Guinea: Epidemiological, Clinical and Therapeutic Aspects},
      journal = {International Journal of Clinical Urology},
      volume = {10},
      number = {1},
      pages = {77-84},
      doi = {10.11648/j.ijcu.20261001.24},
      url = {https://doi.org/10.11648/j.ijcu.20261001.24},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcu.20261001.24},
      abstract = {Introduction: Progressive urological complications represent a urological emergency and an unfavorable prognostic factor in advanced gynecological cancers. This study aimed to describe the epidemiological, clinical, therapeutic, and evolutionary aspects of these complications at the Ignace Deen University Hospital in Conakry. Methodology: Prospective cross-sectional descriptive study conducted in the urology department of Ignace Deen University Hospital over 2 years (January 2024-December 2025). This study included patients with gynecological cancer presenting progressive urological complications. Variables studied were demographic (age, parity), clinical (histological type, FIGO stage, ECOG performance status), paraclinical (serum creatinine, hemoglobin, ultrasound), therapeutic (urinary drainage, oncological treatments), and evolutionary. Upper urinary tract drainage was performed by percutaneous nephrostomy or JJ stent placement. Results: We recorded 88 patients who presented with gynecological cancer with progressive urological complications. The mean age of patients was 54.3±11.5 years. Cervical cancer represented 96.6% (squamous cell carcinomas), predominantly at stage IIIB (61.2%). The general condition of patients was severely deteriorated: 59.1% ECOG III and 40.9% ECOG IV. Isolated bilateral ureterohydronephrosis constituted the main complication (47.7%). JJ stent drainage was successful in 55.7% of patients, percutaneous nephrostomy in 22.7%, with a failure rate of 21.6%. Mean serum creatinine decreased from 10.1 to 6.5 mg/dl (36% reduction), hemoglobin increased from 6.9 to 10.0 g/dl. Exclusive palliative care was provided to 73.9% of patients, 21.6% received chemotherapy. Mean hospital stay was 6.2 days with in-hospital mortality of 11.4%. Conclusion: This study reveals that urological complications of gynecological cancers in Guinea are characterized by late diagnosis and limited therapeutic options. Despite the feasibility of urinary drainage, the massive recourse to palliative care underscores the poor prognosis. Priorities include HPV vaccination, early screening, strengthening of technical facilities, and development of appropriate palliative care structures.},
     year = {2026}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Progressive Urological Complications of Advanced Gynecological Cancers in Guinea: Epidemiological, Clinical and Therapeutic Aspects
    AU  - Mamadou Diawo Bah
    AU  - Alexandre Vahina Gamamou
    AU  - Daouda Kanté
    AU  - Mamadou Abdoulahayo Sina
    AU  - Aboubacar Cherif
    AU  - Lahoumbo Ricardo Gnammi
    AU  - Rémy François Akoï Guilavogui
    AU  - Maïmouna Baldé
    AU  - Thierno Mamadou Oury Diallo
    AU  - Abdoulaye Bobo Diallo
    AU  - Oumar Raphiou Bah
    AU  - Telly Sy
    Y1  - 2026/04/14
    PY  - 2026
    N1  - https://doi.org/10.11648/j.ijcu.20261001.24
    DO  - 10.11648/j.ijcu.20261001.24
    T2  - International Journal of Clinical Urology
    JF  - International Journal of Clinical Urology
    JO  - International Journal of Clinical Urology
    SP  - 77
    EP  - 84
    PB  - Science Publishing Group
    SN  - 2640-1355
    UR  - https://doi.org/10.11648/j.ijcu.20261001.24
    AB  - Introduction: Progressive urological complications represent a urological emergency and an unfavorable prognostic factor in advanced gynecological cancers. This study aimed to describe the epidemiological, clinical, therapeutic, and evolutionary aspects of these complications at the Ignace Deen University Hospital in Conakry. Methodology: Prospective cross-sectional descriptive study conducted in the urology department of Ignace Deen University Hospital over 2 years (January 2024-December 2025). This study included patients with gynecological cancer presenting progressive urological complications. Variables studied were demographic (age, parity), clinical (histological type, FIGO stage, ECOG performance status), paraclinical (serum creatinine, hemoglobin, ultrasound), therapeutic (urinary drainage, oncological treatments), and evolutionary. Upper urinary tract drainage was performed by percutaneous nephrostomy or JJ stent placement. Results: We recorded 88 patients who presented with gynecological cancer with progressive urological complications. The mean age of patients was 54.3±11.5 years. Cervical cancer represented 96.6% (squamous cell carcinomas), predominantly at stage IIIB (61.2%). The general condition of patients was severely deteriorated: 59.1% ECOG III and 40.9% ECOG IV. Isolated bilateral ureterohydronephrosis constituted the main complication (47.7%). JJ stent drainage was successful in 55.7% of patients, percutaneous nephrostomy in 22.7%, with a failure rate of 21.6%. Mean serum creatinine decreased from 10.1 to 6.5 mg/dl (36% reduction), hemoglobin increased from 6.9 to 10.0 g/dl. Exclusive palliative care was provided to 73.9% of patients, 21.6% received chemotherapy. Mean hospital stay was 6.2 days with in-hospital mortality of 11.4%. Conclusion: This study reveals that urological complications of gynecological cancers in Guinea are characterized by late diagnosis and limited therapeutic options. Despite the feasibility of urinary drainage, the massive recourse to palliative care underscores the poor prognosis. Priorities include HPV vaccination, early screening, strengthening of technical facilities, and development of appropriate palliative care structures.
    VL  - 10
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Sections